Table 5.
HT in patients with soft tissue sarcoma, bladder cancer and glioma. Summary of articles reviewed.
| Author | Article Type | Investigation | Total Participants |
Survival Outcome |
|---|---|---|---|---|
| Soft Tissue Sarcoma | ||||
| Issels et al., 2018 [72] | Phase III RCT | HT + NACT vs. NACT alone in localised high-risk STS | N = 341 | Improved response. Improved LPFS and DFS. OS improved (HR = 0.73; p = 0.04). |
| Bladder Cancer | ||||
| Van der Zee et al., 2000 [28] | Phase III RCT | HT + RT vs. RT alone in advanced pelvic tumours | N = 101 (MIBC) | Improved CR. No difference in OS and LC rates. |
| Glioma | ||||
| Mahdavi et al., 2020 [76] | Prospective comparative trial | CTRT vs. CTRT + HT in glioblastoma | N = 38 | Improved response. No difference in OS or performance score change. |